Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

To make it easier for children with asthma to receive care at school, a new study will assess the impact of making the ...

Platform-specific achievement systems transformed an isolated gameplay preference into a visible, competitive subculture. What emerged wasn’t just a playstyle but an ecosystem of tracking tools, ...

The analyses of progression-free survival (PFS) and overall survival (OS) remain on track for late Q1 2026 in the ongoing Phase 2/3 COMPANION-002 ...

Artificial sweeteners have long been cast as either miracle weight-loss allies or metabolic saboteurs — but the science is ...

BD (NYSE: BDX) today announced the first Phasix hernia mesh laparotomy reinforcement case performed in Greece.

SIL204 Demonstrated Significant Tumor Inhibition in Positive Pre Clinical Studies with Activity Across Pancreatic, Colorectal, and Lung Cancer ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...

Regardless of whether you are just dipping your toes into board games or are a long-time fan looking for a big, crunchy match ...

A study published earlier this year in the Journal of Neuro-Oncology indicates that sonodynamic therapy (SDT) safely destroys GBM cells while preserving healthy brain tissue. Using a noninvasive ...

The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...

In this analysis of colorectal cancer patients from 2 clinical trials, researchers aimed to assess the effect of physical activity on overall survival.